netFormulary Central Lancashire Formulary NHS
Lancashire Teaching Hospitals NHS Foundation Trust
Chorley and South Ribble CCG
Greater Preston CCG
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

This Chapter is still under development

 Details...
08.01  Cytotoxic drugs
08.01  Side-effects of cytotoxic drugs
08.01  Drugs for cytotoxic-induced side-effects
08.01.01  Alkylating drugs
08.01.02  Anthracyclines and other cytotoxic antibiotics to top
08.01.03  Antimetabolites
Cytotoxic Drug Cladribine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Treatment of highly active relapsing-remitting multiple sclerosis in adults

 
Link  Cladribine tablets for treating relapsing–remitting multiple sclerosis NICE TA493
   
08.01.04  Vinca alkaloids and etoposide
08.01.05  Other antineoplastic drugs
08.01.05  Amsacrine
08.01.05  Arsenic trioxide to top
08.01.05  Bevacizumab
08.01.05  Bexarotene
08.01.05  Bortezomib
08.01.05  Brentuximab vedotin
08.01.05  Cetuximab to top
08.01.05  Crisantaspase
08.01.05  Dacarbazine and Temozolomide
08.01.05  Erlotinib
08.01.05  Hydroxycarbamide
08.01.05  Imatinab to top
08.01.05  Ipilimumab
08.01.05  Mitotane
08.01.05  Panitumumab
08.01.05  Pentostatin
08.01.05  Platinum compounds to top
08.01.05  Porfimer sodium and temoporfin
08.01.05  Procarbazine
08.01.05  Protein kinase inhibitors
08.01.05  Taxanes
08.01.05  Topoisomerase I inhibitors to top
08.01.05  Trabectedin
08.01.05  Trastuzumab
08.01.05  Tretinoin
08.01.05  Vismodegib
08.02  Drugs affecting the immune response to top
08.02  Immunosuppressant therapy
08.02.01  Antiproliferative immunosuppressants
Cytotoxic Drug Azathioprine
(Chemotherapy/ post- transplant)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Mycophenolate Mofetil
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
Mycophenolate Sodium (Myfortic®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.02.02  Corticosteroids and other immunosuppressants
Ciclosporin
(transplants)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
Dexamethasone
View adult BNF View SPC online View SMC online View childrens BNF  Track Changes
Formulary  
   
Prednisolone
(Immunosuppressant)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Cytotoxic Drug Sirolimus (Rapamune®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
Tacrolimus
(Vivadex)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.02.03  Anti-lymphocyte monoclonal antibodies
Rituximab (MabThera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
BlueTeq
 
   
08.02.04  Other immunomodulating drugs to top
Dimethyl fumarate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
NHS England
BlueTeq

Tecfidera®

Treatment of relapsing-remitting multiple sclerosis

 
Link  NICE TA320: Dimethyl fumarate for multiple sclerosis
   
Fampridine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
Ocrelizumab (Ocrevus®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Treatment of primary progressive multiple sclerosis.   

 

Treating relapsing-remitting multiple sclerosis. 

 
Link  NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
   
Teriflunomide (Aubagio®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
NHS England
BlueTeq
 
Link  NICE TA303: Teriflunomide for relapsing remitting MS
Link  NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
   
Thalidomide (Celgene®)
(haematology)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
08.02.04  Interferon Alfa
Interferon Alfa
(IntronA)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
Link  NICE TA75: Interferon Alfa - Chronic Hepatitis C
   
Peginterferon Alfa (Pegasys®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
Link  NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA300: Hepatitis C - peginterferon alfa
Link  NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Link  NICE TA96: Hepatitis B - peginterferon alfa
   
Peginterferon Alfa (ViraferonPeg®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
08.02.04  Interferon beta
Interferon Beta (Avonex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
Peginterferon Beta-1a (Plegridy®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
08.02.04  Interferon gamma
08.02.04  Aldesleukin
08.02.04  BCG bladder instillation to top
08.02.04  Canakinumab
08.02.04  Dimethyl fumarate
08.02.04  Fingolimod
Fingolimod
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
Homecare
BlueTeq

• Treatment of highly active relapsing remitting multiple sclerosis after 1st line treatment as per NICE TA245

• Treatment of highly active relapsing remitting multiple sclerosis after Natalizumab treatment

 
Link  Drug safety update December 2017: Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk
Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Link  Drug Safety Update September 2019: Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
   
08.02.04  Glatiramer acetate
Glatiramer Acetate (Copaxone®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
NHS England
BlueTeq

Treatment of relapsing-remitting multiple sclerosis in adults

 
Link  NICE CG32: Glatiramer for the treatment of MS
   
08.02.04  Histamine to top
08.02.04  Lenalidomide, pomalidomide, and thalidomide
08.02.04  Mifamurtide
08.02.04  Natalizumab
Natalizumab (Tysabri®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
NHS England
BlueTeq

Treatment of rapidly evolving severe (RES) relapsing-remitting multiple sclerosis

 
Link  NICE TA127: Multiple sclerosis - natalizumab
   
08.02.04  Teriflunomide
08.03  Sex hormones and hormone antagonists in malignant disease to top
08.03.01  Oestrogens
Diethylstilbestrol
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.03.02  Progestogens
Medroxyprogesterone Acetate (Provera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Megestrol Acetate (Megace®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.03.03  Androgens
08.03.04  Hormone antagonists
08.03.04.01  Breast cancer to top
Anastrozole
(Breast cancer)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Exemestane
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Fulvestrant (Faslodex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
Link  NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
   
Letrozole
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Tamoxifen
(Breast cancer/ mastocytosis)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.03.04.02  Prostate cancer and gonadorelin analogues
08.03.04.02  Gonadorelin analogues
08.03.04.02  Anti-androgens
Bicalutamide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Cyproterone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Goserelin (Zoladex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Leuprorelin Acetate (Prostap® 3)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
08.03.04.02  Radiopharmaceuticals
08.03.04.03  Somatostatin analogues to top
Lanreotide (Somatuline® LA)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Octreotide (Sandostatin®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Little or no specific monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Brief prescribing document or information sheet may be required.  

Amber 1

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Minimal monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Full prior agreement about patient’s on-going care must be reached under the shared care agreement.  

Amber 2

Initiated by specialist and transferred to primary care following a successful initiation period. Significant monitoring required on an on-going basis. Full prior agreement about patient’s on-going care must be reached under the shared care agreement. Suitable for enhanced service.  

Black

NOT recommended for use by the NHS in Lancashire. Includes medicines that NICE has not recommended for use and terminated technology appraisals, unless there is a local need.  

Blue

Products shown as blue have different Traffic Light List classifications dependent on indication. See the accompanying text next to the product for further information  

Green

Appropriate for initiation and ongoing prescribing in both primary and secondary care. Generally, little or no routine drug monitoring is required.  

Purple

Low Priority for Prescribing - see Low Priority for Prescribing Policy  

Red

Medicine is supplied by the hospital for the duration of the treatment course. Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.  

Red Specialist Centre

Prescribing restricted to Specialist Centres only  

netFormulary